NCT01039597View on ClinicalTrials.gov

Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Mild to Moderate Ulcerative Colitis
Interventions
DRUG

ORE1001

Oral capsules containing 300 mg of the active, study drug

DRUG

Placebo

placebo capsules

Trial Locations (7)

380009

RECRUITING

Dr, Bhatnagar's Clinic, Ahmedabad

400008

RECRUITING

B.Y.L. Nair Hospital, Bombay

452001

RECRUITING

Gut-n-HEPA Care, Indore

452003

RECRUITING

Amol Gastroenterology Hospital, Indore

560034

RECRUITING

St. John's Medical College Hospital, Bangalore

570002

RECRUITING

Vikram Jyoth Centre for Advanced Gastroenterology, Mysore

N6A5K8

RECRUITING

Robarts Research Institute, London

Sponsors
All Listed Sponsors
lead

Ore Pharmaceuticals, Inc.

INDUSTRY

NCT01039597 - Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis | Biotech Hunter | Biotech Hunter